PMID- 35428555
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220922
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 80
IP  - 3
DP  - 2022 Sep
TI  - Non-cardiovascular readmissions after transcatheter aortic valve replacement: 
      Insights from a Japanese nationwide registry of transcatheter valve therapies.
PG  - 197-203
LID - S0914-5087(22)00070-3 [pii]
LID - 10.1016/j.jjcc.2022.03.010 [doi]
AB  - BACKGROUND: Despite advances in technology and technique, a certain proportion of 
      patients experience non-cardiovascular (CV) readmissions after transcatheter 
      aortic valve replacement (TAVR). However, the actual burden and details of non-CV 
      readmission remain uncertain. METHODS: The Japan-Transcatheter Valve Therapies 
      (J-TVT) registry is a representative nationwide registry, and mandates complete 
      data entry, including 1-year outcomes, for patients undergoing TAVR in Japan. We 
      analyzed the non-CV adverse events (AEs) requiring readmission after the index 
      TAVR procedure between 2013 and 2018. RESULTS: A total of 14,472 patients were 
      analyzed (68.8% of women with median age of 85 years). Overall, 367 patients 
      (2.5%) and 1050 patients (7.2%) had non-CV readmission at 30 days and 1 year, 
      respectively. The most frequent non-CV AEs were related to respiratory (24.0%) 
      and gastrointestinal disease (19.3%). Specifically, 79.0% of all respiratory AEs 
      were pneumonia (infectious, interstitial, or aspiration). Of the gastrointestinal 
      AEs, 22.1% were malignancies, and 18.5% were non-procedural-related bleeding. Age 
      >/=90 years, male sex, body mass index <20 kg/m(2), New York Heart Association 
      functional class III/IV, atrial fibrillation/flutter, malignancy, chronic 
      obstructive pulmonary disease, dialysis, hemoglobin level, albumin level, 
      creatinine level, and non-transfemoral approach were independent predictors of 
      non-CV readmission. CONCLUSIONS: In this analysis of the nationwide registry of 
      patients undergoing TAVR, rate of non-CV readmission at 30 days and 1 year, 
      particularly those related to respiratory and gastrointestinal conditions, were 
      lower than those previously reported. However, caution is still needed when 
      performing TAVR on patients susceptible to these conditions.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Saji, Mike
AU  - Saji M
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. Electronic 
      address: mikesaji8@gmail.com.
FAU - Kumamaru, Hiraku
AU  - Kumamaru H
AD  - Department of Healthcare Quality Assessment, Graduate School of Medicine, 
      University of Tokyo, Tokyo, Japan.
FAU - Kohsaka, Shun
AU  - Kohsaka S
AD  - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
FAU - Higuchi, Ryosuke
AU  - Higuchi R
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Izumi, Yuki
AU  - Izumi Y
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Takamisawa, Itaru
AU  - Takamisawa I
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Tobaru, Tetsuya
AU  - Tobaru T
AD  - Department of Cardiology, Kawasaki Saiwai Hospital, Kanagawa, Japan.
FAU - Shimokawa, Tomoki
AU  - Shimokawa T
AD  - Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Takanashi, Shuichiro
AU  - Takanashi S
AD  - Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo, Japan; 
      Department of Cardiovascular Surgery, Kawasaki Saiwai Hospital, Kanagawa, Japan.
FAU - Shimizu, Hideyuki
AU  - Shimizu H
AD  - Department of Cardiovascular Surgery, Keio University, Tokyo, Japan.
FAU - Takayama, Morimasa
AU  - Takayama M
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
CN  - Japanese TAVR registry participants
LA  - eng
PT  - Journal Article
DEP - 20220412
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
SB  - IM
MH  - Aged, 80 and over
MH  - Aortic Valve/surgery
MH  - *Aortic Valve Stenosis
MH  - Female
MH  - Humans
MH  - Japan/epidemiology
MH  - Male
MH  - Patient Readmission
MH  - Registries
MH  - Risk Factors
MH  - Time Factors
MH  - *Transcatheter Aortic Valve Replacement/adverse effects/methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse events
OT  - Comorbidity
OT  - Transcatheter aortic valve replacement
COIS- Declaration of competing interest Dr. Takamisawa and Dr. Tobaru are proctors for 
      Edwards Lifesciences and Medtronic. Dr. Kumamaru is affiliated with the 
      Department of Healthcare Quality Assessment. The department is supported by 
      National Clinical Database, Johnson & Johnson K.K., and the Nipro corporation. 
      The other authors declare that there are no conflicts of interest.
EDAT- 2022/04/17 06:00
MHDA- 2022/08/03 06:00
CRDT- 2022/04/16 05:19
PHST- 2021/12/27 00:00 [received]
PHST- 2022/02/12 00:00 [revised]
PHST- 2022/03/11 00:00 [accepted]
PHST- 2022/04/17 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
PHST- 2022/04/16 05:19 [entrez]
AID - S0914-5087(22)00070-3 [pii]
AID - 10.1016/j.jjcc.2022.03.010 [doi]
PST - ppublish
SO  - J Cardiol. 2022 Sep;80(3):197-203. doi: 10.1016/j.jjcc.2022.03.010. Epub 2022 Apr 
      12.